Mometasone Furoate Nasal Spray Relieves Moderate-Severe Nasal Congestion in Patients with Seasonal Allergic Rhinitis: A Responder Analysis
Saturday, March 3, 2018
South Hall A2 (Convention Center)
Eduardo R. Urdaneta, MD., Kaan Tunceli, PhD., Davis Gates, PhD.

Nasal Congestion (NC) is the most bothersome symptom of patients with seasonal allergic rhinitis (SAR). Intranasal corticosteroids like mometasone furoate nasal spray (MFNS) are guidelines–preferred treatment for NC.

METHODS: A post-hoc cumulative responder analysis of two clinical studies where NC was the primary endpoint. Subjects ≥12 years of age with ≥2-year SAR history, positive skin test, and moderate or severe NC were randomized to MFNS or placebo in a double-blind parallel design. The primary endpoint was the change from baseline in average AM./PM. reflective NC score averaged over days 1–15. Treatment Response ranging from >0% to >90% improvement was evaluated at 10% intervals; >30% and >50% reductions were further evaluated using the Mietinnen-Nurminen method. Breslow-Day equal odds ratios test was used to justify pooling.

RESULTS: 344 MFNS-treated and 340 placebo-treated subjects were included. For the >30% response, 36.6% of MFNS-treated subjects responded compared to 19.4% of placebo-treated subjects (P<0.001). For the >50% response, 13.4% of MFNS subjects responded compared to 6.5% of placebo-treated subjects (P=0.003). Among MFNS-treated subjects, MFNS response was greater during the second week of treatment; there was no difference between AM and PM reflective NC scores, and between moderate and severe baseline NC.

CONCLUSIONS: MFNS is effective in patients with SAR and moderate-severe nasal congestion.